Directed evolution demonstrates enhanced enantioselectivity and reactivity in biosynthesis of oxindoles.
Enantioenriched 3-hydroxyoxindole scaffolds are prevalent in numerous natural products and exhibit significant biological activity. However, biosynthetic methods for their production remain relatively limited. Here, we report an enantioselective biosynthesis of 3-hydroxy-oxindoles by a myoglobin-based artificial aldolase. By site-specifically incorporating a synthetic secondary amine cofactor into the apo-myoglobin scaffold, the engineered artificial aldolase catalyzes C-C bond formation between isatins and activated ketones, yielding chiral 3-hydroxy-oxindoles with excellent enantioselectivity (up to 96:4 er) and reactivity (up to 99% yield) after directed evolution. The resulting artificial enzyme combines the non-natural catalytic activity of chemical small-molecule catalysts with the tunability of protein scaffolds, enabling efficient access to chiral oxindole architectures with pharmaceutical relevance.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: